SYNLOGIC, INC. — Financial Data
Annual figures from SEC EDGAR XBRL filings (10-K)
These figures are extracted directly from XBRL-tagged financial statements that SYNLOGIC, INC. filed with the SEC as part of its annual 10-K reports. XBRL (eXtensible Business Reporting Language) is a structured data format the SEC requires for machine-readable financial disclosures. Values shown are as reported — negative figures indicate a loss and are shown in red.
Revenue
Total revenue from all business activities — the top line of the income statement. Represents all money earned before any expenses are deducted.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $0 | Mar 12, 2026 |
| FY2025 | Dec 31, 2024 | $8.0K | Mar 12, 2026 |
| FY2024 | Dec 31, 2023 | $3.37M | Mar 6, 2025 |
| FY2023 | Dec 31, 2022 | $1.18M | Mar 19, 2024 |
| FY2022 | Dec 31, 2021 | $1.75M | Mar 29, 2023 |
| FY2021 | Dec 31, 2020 | $545.0K | Mar 17, 2022 |
| FY2020 | Jun 30, 2020 | $445.0K | Mar 25, 2021 |
| FY2020 | Mar 31, 2020 | $100.0K | Mar 25, 2021 |
| FY2020 | Dec 31, 2019 | $1.23M | Mar 25, 2021 |
| FY2020 | Sep 30, 2019 | $305.0K | Mar 25, 2021 |
Net Income
The bottom-line profit — what remains after all operating expenses, interest, taxes, and other costs are deducted. A negative value means the company reported a net loss for the year.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | ($1.01M) | Mar 12, 2026 |
| FY2025 | Dec 31, 2024 | ($23.36M) | Mar 12, 2026 |
| FY2024 | Dec 31, 2023 | ($61.27M) | Mar 6, 2025 |
| FY2023 | Dec 31, 2022 | ($66.15M) | Mar 19, 2024 |
| FY2022 | Dec 31, 2021 | ($60.56M) | Mar 29, 2023 |
| FY2020 | Dec 31, 2020 | ($14.59M) | Mar 25, 2021 |
| FY2020 | Sep 30, 2020 | ($13.22M) | Mar 25, 2021 |
| FY2020 | Jun 30, 2020 | ($15.54M) | Mar 25, 2021 |
| FY2020 | Mar 31, 2020 | ($15.83M) | Mar 25, 2021 |
| FY2020 | Dec 31, 2019 | ($12.80M) | Mar 25, 2021 |
Operating Income
Profit from core business operations before interest expense and income taxes (also known as EBIT). Excludes non-operating items, making it a cleaner measure of operational efficiency than net income.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | ($4.01M) | Mar 12, 2026 |
| FY2025 | Dec 31, 2024 | ($40.95M) | Mar 12, 2026 |
| FY2024 | Dec 31, 2023 | ($55.16M) | Mar 6, 2025 |
| FY2023 | Dec 31, 2022 | ($67.42M) | Mar 19, 2024 |
| FY2022 | Dec 31, 2021 | ($60.77M) | Mar 29, 2023 |
| FY2020 | Dec 31, 2020 | ($14.69M) | Mar 25, 2021 |
| FY2020 | Sep 30, 2020 | ($13.44M) | Mar 25, 2021 |
| FY2020 | Jun 30, 2020 | ($15.94M) | Mar 25, 2021 |
| FY2020 | Mar 31, 2020 | ($16.40M) | Mar 25, 2021 |
| FY2020 | Dec 31, 2019 | ($13.48M) | Mar 25, 2021 |
R&D Expense
Spending on research and development activities — developing new products, improving existing ones, or conducting basic research. High R&D relative to revenue is common in technology and pharmaceutical companies.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $43.0K | Mar 12, 2026 |
| FY2025 | Dec 31, 2024 | $9.15M | Mar 12, 2026 |
| FY2024 | Dec 31, 2023 | $43.97M | Mar 6, 2025 |
| FY2023 | Dec 31, 2022 | $52.04M | Mar 19, 2024 |
| FY2022 | Dec 31, 2021 | $47.13M | Mar 29, 2023 |
| FY2021 | Dec 31, 2020 | $47.47M | Mar 17, 2022 |
| FY2020 | Dec 31, 2019 | $41.91M | Mar 25, 2021 |
| FY2019 | Dec 31, 2018 | $38.03M | Mar 12, 2020 |
| FY2018 | Dec 31, 2017 | $30.34M | Mar 12, 2019 |
| FY2016 | Dec 31, 2016 | $2.34M | Mar 15, 2017 |
Operating Cash Flow
Cash generated from core business operations — a more reliable measure of financial health than net income because it strips out non-cash items like depreciation and one-time charges.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | ($4.36M) | Mar 12, 2026 |
| FY2025 | Dec 31, 2024 | ($31.66M) | Mar 12, 2026 |
| FY2024 | Dec 31, 2023 | ($51.61M) | Mar 6, 2025 |
| FY2023 | Dec 31, 2022 | ($56.89M) | Mar 19, 2024 |
| FY2022 | Dec 31, 2021 | ($52.20M) | Mar 29, 2023 |
| FY2021 | Dec 31, 2020 | ($39.55M) | Mar 17, 2022 |
| FY2020 | Dec 31, 2019 | ($75.47M) | Mar 25, 2021 |
| FY2019 | Dec 31, 2018 | ($42.47M) | Mar 12, 2020 |
| FY2018 | Dec 31, 2017 | ($31.06M) | Mar 12, 2019 |
Capital Expenditures (Capex)
Cash spent on acquiring or upgrading physical assets — property, equipment, and infrastructure. High capex businesses include manufacturing, telecom, and energy companies.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $0 | Mar 12, 2026 |
| FY2025 | Dec 31, 2024 | $14.0K | Mar 12, 2026 |
| FY2024 | Dec 31, 2023 | $214.0K | Mar 6, 2025 |
| FY2023 | Dec 31, 2022 | $728.0K | Mar 19, 2024 |
| FY2022 | Dec 31, 2021 | $679.0K | Mar 29, 2023 |
| FY2021 | Dec 31, 2020 | $395.0K | Mar 17, 2022 |
| FY2020 | Dec 31, 2019 | $1.25M | Mar 25, 2021 |
| FY2019 | Dec 31, 2018 | $5.65M | Mar 12, 2020 |
| FY2018 | Dec 31, 2017 | $2.58M | Mar 12, 2019 |
| FY2017 | Dec 31, 2016 | $1.84M | Mar 20, 2018 |
Total Assets
The total value of everything the company owns or controls — cash, investments, receivables, property, equipment, and intangibles. Reported as of fiscal year end.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $15.45M | Mar 12, 2026 |
| FY2025 | Dec 31, 2024 | $19.83M | Mar 12, 2026 |
| FY2024 | Dec 31, 2023 | $75.55M | Mar 6, 2025 |
| FY2023 | Dec 31, 2022 | $110.87M | Mar 19, 2024 |
| FY2022 | Dec 31, 2021 | $174.74M | Mar 29, 2023 |
| FY2021 | Dec 31, 2020 | $143.84M | Mar 17, 2022 |
| FY2020 | Dec 31, 2019 | $188.57M | Mar 25, 2021 |
| FY2019 | Dec 31, 2018 | $140.34M | Mar 12, 2020 |
| FY2018 | Dec 31, 2017 | $99.70M | Mar 12, 2019 |
| FY2017 | Dec 31, 2016 | $20.04M | Mar 20, 2018 |
Total Liabilities
All financial obligations owed to outside parties — including debt, accounts payable, accrued expenses, and deferred revenue. Subtracting liabilities from total assets gives stockholders' equity.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2016 | Dec 31, 2016 | $3.81M | Mar 15, 2017 |
| FY2016 | Dec 31, 2015 | $5.90M | Mar 15, 2017 |
Stockholders Equity
The net worth attributable to shareholders: total assets minus total liabilities. Also called book value. Can be negative if liabilities exceed assets, which is common in capital-intensive industries.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $11.86M | Mar 12, 2026 |
| FY2025 | Dec 31, 2024 | $12.75M | Mar 12, 2026 |
| FY2025 | Dec 31, 2023 | $32.77M | Mar 12, 2026 |
| FY2024 | Dec 31, 2022 | $82.61M | Mar 6, 2025 |
| FY2023 | Dec 31, 2021 | $147.27M | Mar 19, 2024 |
| FY2022 | Dec 31, 2020 | $115.14M | Mar 29, 2023 |
| FY2021 | Dec 31, 2019 | $156.91M | Mar 17, 2022 |
| FY2020 | Dec 31, 2018 | $124.10M | Mar 25, 2021 |
| FY2019 | Dec 31, 2017 | $85.04M | Mar 12, 2020 |
| FY2018 | Dec 31, 2016 | $8.50M | Mar 12, 2019 |
Retained Earnings
Cumulative net income kept by the company rather than distributed as dividends. A growing retained earnings balance indicates consistent profitability; a deficit indicates cumulative losses.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | ($442.66M) | Mar 12, 2026 |
| FY2025 | Dec 31, 2024 | ($441.65M) | Mar 12, 2026 |
| FY2024 | Dec 31, 2023 | ($418.29M) | Mar 6, 2025 |
| FY2023 | Dec 31, 2022 | ($357.02M) | Mar 19, 2024 |
| FY2022 | Dec 31, 2021 | ($290.87M) | Mar 29, 2023 |
| FY2021 | Dec 31, 2020 | ($230.31M) | Mar 17, 2022 |
| FY2020 | Dec 31, 2019 | ($171.14M) | Mar 25, 2021 |
| FY2019 | Dec 31, 2018 | ($119.77M) | Mar 12, 2020 |
| FY2018 | Dec 31, 2017 | ($71.65M) | Mar 12, 2019 |
| FY2017 | Dec 31, 2016 | ($31.25M) | Mar 20, 2018 |
Cash & Equivalents
Highly liquid assets the company holds — cash on hand, bank balances, and short-term investments with maturities of three months or less. A key indicator of short-term financial health.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $14.67M | Mar 12, 2026 |
| FY2025 | Dec 31, 2024 | $18.86M | Mar 12, 2026 |
| FY2024 | Dec 31, 2023 | $23.96M | Mar 6, 2025 |
| FY2023 | Dec 31, 2022 | $15.86M | Mar 19, 2024 |
| FY2022 | Dec 31, 2021 | $16.44M | Mar 29, 2023 |
| FY2021 | Dec 31, 2020 | $32.51M | Mar 17, 2022 |
| FY2020 | Dec 31, 2019 | $26.18M | Mar 25, 2021 |
| FY2019 | Dec 31, 2018 | $11.25M | Mar 12, 2020 |
| FY2018 | Dec 31, 2017 | $58.44M | Mar 12, 2019 |
| FY2017 | Dec 31, 2016 | $14.59M | Mar 20, 2018 |
EPS (Basic)
Net income divided by the weighted average shares outstanding. Basic EPS does not account for dilutive securities like options or convertible bonds — use diluted EPS for a more conservative view.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | 0 | Mar 12, 2026 |
| FY2025 | Dec 31, 2024 | (1) | Mar 12, 2026 |
| FY2024 | Dec 31, 2023 | (9) | Mar 6, 2025 |
| FY2023 | Dec 31, 2022 | (13) | Mar 19, 2024 |
| FY2022 | Dec 31, 2021 | (1) | Mar 29, 2023 |
EPS (Diluted)
Net income divided by the fully diluted share count — including all potential shares from options, warrants, and convertible instruments. The more conservative and widely cited EPS figure.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | 0 | Mar 12, 2026 |
| FY2025 | Dec 31, 2024 | (1) | Mar 12, 2026 |
| FY2024 | Dec 31, 2023 | (9) | Mar 6, 2025 |
| FY2023 | Dec 31, 2022 | (13) | Mar 19, 2024 |
| FY2022 | Dec 31, 2021 | (1) | Mar 29, 2023 |
Shares Outstanding
Total common shares issued and held by all shareholders, excluding treasury shares. Combined with market price gives market capitalization.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | 11.70M | Mar 12, 2026 |
| FY2025 | Dec 31, 2024 | 11.70M | Mar 12, 2026 |
| FY2024 | Dec 31, 2023 | 9.19M | Mar 6, 2025 |
| FY2024 | Nov 9, 2023 | 539,685 | Mar 6, 2025 |
| FY2023 | Dec 31, 2022 | 4.45M | Mar 19, 2024 |
| FY2022 | Dec 31, 2021 | 69.70M | Mar 29, 2023 |
| FY2021 | Dec 31, 2020 | 38.18M | Mar 17, 2022 |
| FY2020 | Dec 31, 2019 | 32.27M | Mar 25, 2021 |
| FY2019 | Dec 31, 2018 | 25.40M | Mar 12, 2020 |
| FY2018 | Dec 31, 2017 | 16.27M | Mar 12, 2019 |